New drug duo takes on tough lymphoma
NCT ID NCT06883526
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 9 times
Summary
This study tests a combination of two drugs, ZG005 and gecacitinib, in about 60 adults with relapsed or refractory lymphoma (cancer that returned or didn't respond to prior therapy). The first part finds a safe dose; the second part checks if the combo shrinks tumors. Participants must have a confirmed lymphoma diagnosis and no cancer spread to the brain or serious heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
Conditions
Explore the condition pages connected to this study.